NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
Revolution Medicines, Inc.
Adaptimmune
Novartis
CRISPR Therapeutics
Sanofi
University Health Network, Toronto
Hoffmann-La Roche
Creative Biosciences (Guangzhou) Co., Ltd.
Intensity Therapeutics, Inc.
Advaxis, Inc.
Latin American Cooperative Oncology Group
Takeda
Ludwig Institute for Cancer Research
Vaccinex Inc.
Genocea Biosciences, Inc.
UCB Pharma
Takeda
Duke University
Hôpital Cochin
Eli Lilly and Company
ChineseAMS
Istituto Clinico Humanitas
Mereo BioPharma
Peking University People's Hospital
GlaxoSmithKline
BioNumerik Pharmaceuticals, Inc.
Northwell Health
Dartmouth-Hitchcock Medical Center
National Institutes of Health Clinical Center (CC)
Sunesis Pharmaceuticals
Celgene
Sunesis Pharmaceuticals
Onkovis GmbH
Merck Sharp & Dohme LLC
AbbVie
H. Lee Moffitt Cancer Center and Research Institute
Sanofi
AHS Cancer Control Alberta
Eli Lilly and Company
Stanford University
Merck KGaA, Darmstadt, Germany
Onkovis GmbH
AVEO Pharmaceuticals, Inc.
Bristol-Myers Squibb
AstraZeneca
AstraZeneca
Pfizer
Sanofi
AstraZeneca